P/E ratio for Arbutus Biopharma (ABUS)
P/E ratio as of July 2025 (TTM): -7.61
According to Arbutus Biopharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.61364. At the end of 2024 the company had a P/E ratio of -8.42.
P/E ratio history for Arbutus Biopharma from 2008 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -8.42 | 48.21% |
| 2023 | -5.68 | 12.17% |
| 2022 | -5.07 | 8.35% |
| 2021 | -4.67 | 25.66% |
| 2020 | -3.72 | 293.8% |
| 2019 | -0.9446 | -71.42% |
| 2018 | -3.31 | 2.12% |
| 2017 | -3.24 | 856.62% |
| 2016 | -0.3384 | -89.65% |
| 2015 | -3.27 | -59.34% |
| 2014 | -8.04 | -4.45% |
| 2013 | -8.41 | -459.13% |
| 2012 | 2.34 | -238.99% |
| 2011 | -1.69 | -55.56% |
| 2010 | -3.79 | -32.34% |
| 2009 | -5.61 | 419.99% |
| 2008 | -1.08 | -88.26% |
| 2007 | -9.18 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 NRC Health
NRC | 13.5 | -277.70% | 🇺🇸 USA |
 Nymox Pharmaceutical NYMX | -3.33 | -56.22% | Bahamas |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.